Subcutaneous Biologic Drugs and Affiliated Technologies Market is projected to be worth over USD 180 billion by 2030
More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis

RootsAnalysis has done a detailed report on SubcutaneousBiologics, Technologies and Drug Delivery Systems Market, 2021-2030covering key aspects of the industry and identifying future growthopportunities.

Severalapproved therapeutic products, which are currently available as intravenousdosage forms, are being reformulated and evaluated for subcutaneous administration.Further, many existing drug delivery devices, including prefilled syringes, peninjectors, auto injectors, needle-free injectors and large volume wearableinjectors, have been / are being designed for subcutaneous administration ofbiologics.

The USD 180+ billion (by2030) financial opportunity associated with subcutaneous biologics, affiliateddrug delivery systems and subcutaneous formulation technology licensing deals,has been analyzed across the following segments:

GetDetailed Analysis:

KeyMarket Insights

·       Eminent representatives frombiopharmaceutical companies confirm the rising interest in the concept ofsubcutaneous drug delivery, highlighting some of the key drivers and upcomingtrends in this domain

·       More than 100 subcutaneous biologics havebeen approved and over 350 such drug candidates are being evaluated in theclinical stages of development, for the treatment of a wide variety of diseaseindications

·       Antibodies and protein therapeutics representthe majority of subcutaneous biologics that are available / underinvestigation, designed for use against various therapeutic areas and havingdifferent dosing regimens

·       Advances in drug delivery have led to thedevelopment of novel technology platforms, enabling the administration ofhighly viscous formulations, and supporting the development of subcutaneousdosage forms

·       Several technology developers haveout-licensed their proprietary platforms to pharmaceutical companies in orderto enable them to develop subcutaneous formulations of their approved /pipeline products

·       The increasing interest in this field isreflected in the yearly growth in partnership activity, including a number oflicensing and product development deals related to subcutaneous formulations ofvarious drug candidates

·       There are several new and innovative drugdelivery systems that facilitate subcutaneous administration; we identifiedover 300 such systems that are presently available / under development

·       With several self-medication enablingdevices, such as wearable injectors and autoinjectors, available in the market,developers are actively differentiating their offerings by incorporatingadvanced, patient-friendly features

·       The market is anticipated to be worth overUSD 180 billion in 2030; the projected opportunity is likely to be distributedacross various types of molecules that are developed / being developed fordifferent disease indications

·       Pre-filled syringes continue to dominate thecurrent market of subcutaneous drug delivery systems; technology developers areexpected to continue relying on licensing agreements as their primary source ofrevenues.

MarketSegment @ SubcutaneousBiologic Drugs and Affiliated Technologies Market Analysis

Phaseof development

·       Approved

·       Pre-registration & Phase III

·       Phase II & Phase II/III

Typeof molecule

·       Cell and gene therapies

·       Monoclonal antibodies

·       Proteins

·       Peptides (recombinant)

·       Vaccines

·       Others

Targettherapeutic area

·       Autoimmune disorders

·       Blood disorders

·       Bone disorders

·       Genetic disorders

·       Metabolic disorders

·       Neurological disorders

·       Oncological disorders

·       Respiratory disorders

·       Others

Typeof drug delivery system

·       Large volume wearable injectors

·       Autoinjectors

·       Prefilled syringes

·       Needle-free injectors

·       Drug reconstitution systems

·       Revenues from licensing deals

·       Upfront payments

·       Milestone payments

Keygeographical regions

·       North America

·       Europe

·       Asia Pacific

·       Rest of the World

Requestfor PDF Sample: SubcutaneousBiologic Drugs and Affiliated Technologies Market Size and share 2021

The Subcutaneous Biologics, Technologies and DrugDelivery Systems (3rd Edition), 2020-2030 report features the followingcompanies, which we identified to be key players in this domain:

MarketKey Players:

·       Adocia

·       Ajinomoto Bio-Pharma Services

·       Arecor

·       Alteogen

·       Ascendis Pharma

·       Avadel Pharmaceuticals

·       Camurus

·       Creative BioMart

·       Creative Biolabs

·       DURECT

·       Eagle Pharmaceuticals

·       Halozyme Therapeutics

·       MedinCell

·       Xeris Pharmaceuticals

·       Serina Therapeutics

Tableof Contents

1.       Preface

2.       ExecutiveSummary

3.       Introduction

4.       SubcutaneousBiologics: Current Market Landscape

5.       Case Study:Leading Subcutaneous Biologics

6.       SubcutaneousFormulation Technologies: Current Market Landscape

7.       SubcutaneousFormulation Technology Developers: Company Competitiveness Analysis

8.       SubcutaneousFormulation Technology Developers: Company Profiles

9.       Partnershipsand Collaborations

10.     SubcutaneousDrug Delivery Systems: Current Market Landscape

11.     SwotAnalysis

12.     MarketForecast and Opportunity Analysis

13.     ConcludingRemarks

14.     ExecutiveInsights

15.     Appendix1:  Tabulated Data

16.     Appendix 2:List Of Companies And Organization

RequestFor Customization:

AlsoVisit Our Latest Publication:

Cloud-based Solutions for Drug Discovery,Development and Manufacturing Market

CAR-T Cell Therapies Market

Patient Recruitment and Retention ServicesMarket

mRNA Therapeutics and Vaccines Market

T-Cell (CAR-T, TCR, and TIL) TherapiesMarket

AboutRoots Analysis

RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at [email protected]


RootsAnalysis Private Limited


+1(415) 800 3415

[email protected]


You may also like

Facebook Conversations

Disqus Conversations